Core Insights - Artiva Biotherapeutics has appointed Dr. Subhashis Banerjee as Chief Medical Officer, enhancing its development team focused on autoimmune diseases and cell therapy [1][2] - Dr. Banerjee has over 20 years of clinical development experience, previously holding significant roles at Bristol Myers Squibb and VYNE Therapeutics [1][2] - The company aims to advance its AlloNK® program for treating B-cell driven autoimmune diseases, leveraging Dr. Banerjee's expertise in regulatory approval of major therapies [2][5] Company Overview - Artiva Biotherapeutics is a clinical-stage biotechnology company dedicated to developing safe and effective cell therapies for autoimmune diseases and cancers [5][6] - The lead program, AlloNK®, is a non-genetically modified NK cell therapy designed to enhance the efficacy of monoclonal antibodies for B-cell depletion [5] - Artiva was founded in 2019 as a spin-out from GC Cell, holding exclusive rights to NK cell manufacturing technology outside of Asia, Australia, and New Zealand [5] Recent Appointments - Dr. David Moriarty has been appointed as SVP of Clinical Operations, bringing nearly 25 years of experience in clinical research related to cell therapy and autoimmune diseases [3][4] - Benjamin Dewees has joined as SVP of Regulatory Affairs, with over 25 years of experience in regulatory affairs across various therapeutic areas [9] - Feng Xu has been appointed as SVP of Biometrics, contributing over 20 years of clinical development experience, including successful global regulatory filings [9]

Core Viewpoint - Artiva Biotherapeutics, Inc. is set to present at the 24th Annual Needham Virtual Healthcare Conference on April 7, 2025, highlighting its focus on developing cell therapies for autoimmune diseases and cancers [1][2]. Company Overview - Artiva Biotherapeutics is a clinical-stage biotechnology company founded in 2019, specializing in cell therapies for autoimmune diseases and cancers [3]. - The company's lead program, AlloNK, is an allogeneic, off-the-shelf, non-genetically modified, cryopreserved NK cell therapy candidate aimed at enhancing the efficacy of monoclonal antibodies for B-cell depletion [3]. - AlloNK is currently undergoing clinical trials for systemic lupus erythematosus and is involved in an investigator-initiated basket trial for multiple autoimmune indications [3]. - Artiva's pipeline also includes CAR-NK candidates targeting both solid and hematologic cancers [3]. - The company has exclusive worldwide rights (excluding Asia, Australia, and New Zealand) to GC Cell's NK cell manufacturing technology and programs, following a strategic partnership [3]. Event Participation - Members of the Artiva management team will engage in investor meetings during the conference, and a live webcast of the presentation will be available for the public [2]. - A replay of the webcast will be accessible for 90 days post-event [2]. Contact Information - For investor inquiries, Neha Krishnamohan can be contacted at ir@artivabio.com, and for media inquiries, Jessica Yingling, Ph.D., can be reached at jessica@litldog.com or +1.858.344.8091 [6].